Based on the drug list used in the current risk-assessment tool in combination with the other risk variables, many psychiatric inpatients, especially geriatric patients, are inaccurately assessed ...
And how much does it really cost to bring a drug to market? Increasingly, though, these debates are happening when everyone knows that the list price is not the ‘real’ price to be paid ...